Research programme: cancer therapy - STIL BioTechnologies

Drug Profile

Research programme: cancer therapy - STIL BioTechnologies

Alternative Names: SB 144; SSP 1; SSP 5; YM 17; YM 27

Latest Information Update: 26 Jan 2007

Price : $50

At a glance

  • Originator STIL BioTechnologies
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Non-small cell lung cancer

Most Recent Events

  • 16 Jul 2003 Preclinical trials in Non-small cell lung cancer in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top